Document is current

Article History

Received: 15 September 2025

Accepted: 25 November 2025

First Online: 16 December 2025

Disclosure

: TAK has received speaker honoraria from Exact Sciences; has received compensation for serving on the FES Steering Committee for GE Healthcare, for serving on an advisory board for Veracyte, and for serving as faculty for PrecisCa cancer information service. EAM has received compensation for participating in scientific advisory boards for AstraZeneca, BioNTech, Merck, and Moderna; has undertaken uncompensated service on steering committees for Bristol Myers Squibb and Roche/Genentech; has received speaker’s honoraria and travel support from Merck Sharp & Dohme and institutional research support from Roche/Genentech (via SU2C grant) and Gilead; has received research funding from Susan Komen for the Cure, for which she serves as a scientific advisor; and has participated as an uncompensated member of the American Society of Clinical Oncology Board of Directors. JMB has received consulting support from The Agency for Healthcare Research and Quality and AbbVie Inc and serves on the medical device advisory board for the US Food and Drug Administration. SPM is supported by the American College of Surgeons Faculty Research Fellowship and the American Society of Clinical Oncology Conquer Cancer Career Development Award. EP has received grant funding to the institution from Merck Foundation, Pfizer, Genentech, Guardent Health, and Astra Zeneca and has served as a consultant for GSK, Merck, and Novartis. All remaining authors report no conflicts of interest.